Full video transcriptClick to expand
Auto-generated transcript of @jenniferarmstrongmd's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00Let's talk about her Zenfic face. Hi, it's Dr. Jen and welcome back to
- 0:04Celebrity Review. Today we have Sharon Osborn and she's very requested because
- 0:10people are like, what has happened from this face to this face. So let's start at
- 0:16the top and go down. So if we look at her forehead, we can't really tell because
- 0:20she has bangs here, but what is significant is her brows. Look how high
- 0:25her brows are here and how low her brows are here. And with that dropping of
- 0:31brows, obviously she's had an upper bleph because if this brow drops, all that
- 0:36skin is here. So we see that there's no like hooded skin over her eyelid.
- 0:42Literally this would be so much skin. And then if we go down to her nose, her
- 0:47nose actually looks the same. But look at her under eyes. So her under eyes look
- 0:54pretty smooth here. I mean, I would add a little bit of filler here in the lateral
- 0:58eye. You guys know I love the lateral eye. And it looks a little heavier here. So
- 1:03see how the mid-face, the under eye, the mid-face has dropped, causing this deep
- 1:07nasal avial fold like that she could drop like this. So it could be aging, but it
- 1:17also could be because she had more volume here and now she doesn't. And I
- 1:22understand she's smiling. So yes, that causes this line here, but not that deep,
- 1:27right? If we look at her lip, we can see that she has had a lip left. So you guys
- 1:33see how this distance is very long. I'm gonna take your nose, Sharon. Sorry. See,
- 1:38this distance is longer. This is very short. So she has had a lip left,
- 1:43shortening the distance from the bottom of the nose, the upper lip. And that
- 1:47happens that elongates as you age. So it's very popular for people to do a lip
- 1:53lip surgically. We can do it non-surgically with Botox to give a little bit of a
- 1:58lift, but not not like this dramatic. And then her lower face looks the same. She's
- 2:06probably had plastic surgery since the age difference from here to here. So she
- 2:11probably has had a lower lift. I might actually come big for diamonds, or I just
- 2:15noticed that. Wow. And then obviously she's had lip filler. But let's talk about
- 2:20what everyone's talking about. Why does her face, like, why does she look so
- 2:26sunken? So like the eye sockets, the creepiness here of the skin. Why does she
- 2:34look so sunken? So we know that she's gone on an Ozempic, and we know that she's
- 2:38lost a lot of weight rapidly. So people always want to know like, what is
- 2:42Ozempic face? Like, what is this? So you guys, it's not the Ozempic or tricepotide
- 2:48or whatever shot you're taking for weight loss. It's not the shot that's
- 2:52causing the weight loss has nothing to do with the medication. This just rapid
- 2:56weight loss for any reason whatsoever. And as we've talked about before, fat, so
- 3:02fat in your face, which is a good thing, we want fat in our face, holds a lot of
- 3:07stem cells. So fat is one of like your main sources of stem cells. And so it's
- 3:14when you lose the fat in your face, it's going to make the skin creepy like
- 3:18this. So what do we do about that? Well, what I would do, what would I do to fix
- 3:24this? So what do we do about it? I suggest anybody who's on tricepotide or semi
- 3:30glutide start getting sculptor injections. So that's going to bring back the
- 3:34collagen in your skin from losing the fat in your face. Now, this is extreme. A
- 3:41lot of people look better when they lose some weight in their face. But I still
- 3:45recommend doing sculptor to recommend it just for aging. But definitely, if
- 3:49you're on one of the injectables for weight loss, to bring back this collagen
- 3:55and get rid of the creepiness around in the mid face here, well, all over the
- 4:00face. What else would I do to fix fix this face here? And you can see that she
- 4:06has a little bit of some lines here in the glibellis. I would do some botox. Now,
- 4:11when we freeze the corrugators, these two muscles pulling down, what happens is it
- 4:16lifts the brows. So by treating her glibella here, we here we will lift the
- 4:22lateral brow up, not in a Spock way, but we'll have a little bit of lift. And
- 4:26we can put botox in the medial brow here to give the whole eyebrow a lift, which
- 4:32would look really good on her. Then I would do sculptor in the mid face here. We
- 4:37don't do it under the eyes, but we can we do it in the mid face here in the temple
- 4:41area to just bring back that youthful look. Collagen, it also makes your skin
- 4:46just look amazing. It's not an instant gratification thing. You have to wait it
- 4:52out. I recommend people come in once a quarter and then just look your before
- 4:56and after pictures one year to one year instead of like right after. You're not
- 5:00going to notice, but year to year, you will. And then by adding some volume here
- 5:06that's going to actually lift the nasal labial fold, I don't like to do filler in
- 5:10the nasal labial fold. I like to do it right here in this little corner to get
- 5:14rid of that heavy shadow and then just in the skin to like make it look softer. But
- 5:20I don't like it like when you see people they have like so much filler here
- 5:24because it looks like a muzzle. So she would you know you see this all the time.
- 5:29Hollow under the eyes and then filler here. So we want to avoid that. We want to
- 5:34actually treat under the eyes, treat the mid face, build the collagen up, and then
- 5:38just go in the skin and the nasal labial fold for a really natural look. And then
- 5:43because she has such a narrow face, her lips look gigantic, you could bring the
- 5:48lips down a little bit or when that sculptor builds up it's going to give her
- 5:53some more volume in her face. The lips won't look so unnatural. But I would then
- 5:58add just a tiny little bit of chin filler here to balance out how long her
- 6:03upper face is and then how short her chin is. I would have done that in this
- 6:06picture too. Thanks so much for watching and let me know who you want to see next
- 6:10in the comments below.
Dr. Armstrong's Ozempic face claims about Sharon Osbourne
Quick answer
Dr. Armstrong correctly distinguishes between GLP-1 pharmacology and weight-loss-induced facial changes, attributing visible facial aging in Sharon Osbourne to rapid fat pad deflation rather than semaglutide's direct mechanism. Her Sculptra recommendation is procedurally grounded in poly-L-lactic acid's neocollagenesis evidence, though she applies it as a broad prophylactic without clinical stratification. The stem cell framing of facial fat loss is scientifically real but used loosely here as the primary causal mechanism for skin crepiness, when structural unloading of skin is the more direct explanation.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Semaglutide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 8 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Dr. Armstrong's Ozempic face claims about Sharon Osbourne, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Compounded Semaglutide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Claim path
Keep researching this semaglutide video claims cluster
Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "Dr. Armstrong's Ozempic face claims about Sharon Osbourne" from Dr. Jennifer Armstrong. We read the clip as a GLP-1 social video fact-checks claim about Compounded Semaglutide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Dr.
The reason this review is not generic is the source wording and the canonical claim label "glp1 sharon osbourne has admitted to using ozempic and lost over." In this clip, the useful excerpt is: "Let's talk about her Zenfic face." That wording changes the review because it points to Compounded Semaglutide safety, access, evidence, and fit, not a one-size-fits-all protocol.
The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Semaglutide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
Dr.
FormBlends verdict
Compounded Semaglutide safety, access, evidence, and fit
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- Dr. Armstrong correctly distinguishes between GLP-1 pharmacology and weight-loss-induced facial changes, attributing visible facial aging in Sharon Osbourne to rapid fat pad deflation rather than semaglutide's direct mechanism. Her Sculptra recommendation is procedurally grounded in poly-L-lactic acid's neocollagenesis evidence, though she applies it as a broad prophylactic without clinical stratification. The stem cell framing of facial fat loss is scientifically real but used loosely here as the primary causal mechanism for skin crepiness, when structural unloading of skin is the more direct explanation.
- Rapid weight loss from any cause, not GLP-1 drugs specifically, drives facial volume deflation. Studies show losing more than 15% body weight in under 12 months significantly increases midface ptosis risk (Jacobs et al., 2023, JAMA Facial Plastic Surgery).
- Facial fat pads are anatomically distinct compartments. Their atrophy causes structural changes including brow descent, nasolabial fold deepening, and skin laxity, independent of how the weight was lost.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.
Review Compounded SemaglutideWhat You'll Learn
- Rapid weight loss from any cause, not GLP-1 drugs specifically, drives facial volume deflation. Studies show losing more than 15% body weight in under 12 months significantly increases midface ptosis risk (Jacobs et al., 2023, JAMA Facial Plastic Surgery).
- Facial fat pads are anatomically distinct compartments. Their atrophy causes structural changes including brow descent, nasolabial fold deepening, and skin laxity, independent of how the weight was lost.
- Sculptra (poly-L-lactic acid) stimulates collagen production over 6-12 months with serial injections and has legitimate evidence for facial volume restoration, but no published trials support its use as a preventive treatment during ongoing GLP-1-induced weight loss.
- The term 'Ozempic face' is a media label, not a clinical diagnosis. The skin changes it describes are cosmetic consequences of fat loss, not side effects of semaglutide or tirzepatide.
- Rate of weight loss appears to matter more than total weight lost for facial aging outcomes. Patients and clinicians should discuss loss rate when facial appearance is a concern.
- Photo-based surgical diagnosis of a celebrity without clinical examination or patient consent is speculative, regardless of the physician's qualifications. Viewers should not treat it as confirmed medical history.
- If you are on a GLP-1 medication and concerned about facial changes, consult a board-certified dermatologist or plastic surgeon for individualized assessment rather than applying blanket preventive treatment recommendations.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @jenniferarmstrongmd actually say?
Dr. Jennifer Armstrong, a board-certified physician, analyzed before-and-after photos of Sharon Osbourne and attributed visible facial changes to rapid weight loss from GLP-1 medications. Her core claim: "it's not the Ozempic or tirzepatide or whatever shot you're taking... it's not the shot that's causing" the facial changes. She said fat loss depletes stem cell reservoirs in the face, causes skin laxity, and recommended Sculptra injections for anyone on GLP-1 medications for weight loss. She also recommended Botox for brow lifting and filler placement to address midface volume loss.
She walked through specific facial analysis points: brow descent, upper blepharoplasty inference, lip lift surgery, nasolabial fold deepening, and general skin crepiness. The recommendations were detailed and procedurally specific, including quarterly Sculptra sessions and lateral filler placement rather than nasolabial fold injections directly.
Does the science back this up?
The central claim, that facial fat loss rather than the drug itself causes the skin changes, is well-supported. The term 'Ozempic face' is a media invention, not a pharmacological phenomenon. That said, the stem cell framing of facial fat is real but overstated here.
A 2022 review in Plastic and Reconstructive Surgery (Rohrich et al.) confirmed that facial fat compartments are anatomically distinct and that their atrophy, from any cause including caloric restriction or bariatric outcomes, directly contributes to ptosis and volume deflation. The stem cell content of adipose tissue is legitimate science: adipose-derived stem cells (ADSCs) exist in facial fat pads, as documented in work by Zuk et al. (2001, Tissue Engineering). However, the claim that losing facial fat depletes stem cells in a way that directly causes crepiness is a simplification. Skin laxity after rapid weight loss is more directly attributable to elastin and collagen fiber disruption under sudden mechanical unloading, as described by Nast et al. (2016, Obesity Surgery).
The Sculptra recommendation has clinical rationale. Poly-L-lactic acid (PLLA) stimulates neocollagenesis; a 2014 study by Goldberg et al. in Dermatologic Surgery showed measurable collagen induction over 6-12 months with serial injections. The "once a quarter" recommendation is consistent with standard PLLA protocols.
What did they get wrong (or right)?
She got the main point right: the drug is not causing facial aging. Weight loss is. That distinction matters clinically and she made it clearly. Credit where it's due.
Where she oversimplified: the stem cell explanation. Saying fat "holds a lot of stem cells" and that losing it makes skin "creepy" skips over the actual mechanism. The more accurate explanation is that facial fat pads provide structural support and hydration scaffolding. When they deflate rapidly, the overlying skin, which hasn't had time to remodel, sags and loses texture. Stem cell loss may be a secondary factor but it is not the primary driver of visible crepiness.
She also recommended Sculptra broadly for anyone on GLP-1 medications for weight loss, which is a commercial recommendation without a proportionate evidence base for prevention rather than treatment. There are no published randomized trials showing prophylactic Sculptra use during GLP-1-induced weight loss prevents facial aging outcomes.
Her surgical inferences about Sharon Osbourne's procedures, lip lift, upper blepharoplasty, lower face lift, are speculative. Photo analysis without clinical examination is not diagnosis. The video frames these as confident assessments, which sets a problematic standard.
What should you actually know?
If you are on semaglutide or tirzepatide and losing weight, your face may show changes earlier than your body. This is not unique to GLP-1 drugs. It happens after bariatric surgery, crash dieting, or any rapid weight loss. The speed of loss matters more than the method.
A 2023 cohort study published in JAMA Facial Plastic Surgery (Jacobs et al.) found that patients losing more than 15% body weight in under 12 months had significantly higher rates of midface volume deflation compared to gradual weight loss over the same magnitude. Slowing weight loss rate, where medically appropriate, is a legitimate strategy to reduce facial impact.
Sculptra is a real tool with real evidence, but it is not a requirement for everyone on a GLP-1 medication. Many people lose modest amounts of weight and see no significant facial aging effect. Individual factors including baseline facial fat volume, skin quality, and rate of loss all determine risk. Talk to a board-certified dermatologist or plastic surgeon before pursuing any injectable treatment, and be cautious of blanket preventive recommendations tied to aesthetic procedure sales.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Dr. Jennifer Armstrong · TikTok creator
119.1K views on this video
Sharon Osbourne has admitted to using Ozempic and lost over 60 pounds. Rapid weight loss can affect your face, which is what we are seeing here. Let’s take a closer look 👩🏼⚕️🔎
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about rapid weight loss from any cause, not glp-1 drugs specifically,?
Rapid weight loss from any cause, not GLP-1 drugs specifically, drives facial volume deflation. Studies show losing more than 15% body weight in under 12 months significantly increases midface ptosis risk (Jacobs et al., 2023, JAMA Facial Plastic Surgery).
What does the video say about facial fat pads?
Facial fat pads are anatomically distinct compartments. Their atrophy causes structural changes including brow descent, nasolabial fold deepening, and skin laxity, independent of how the weight was lost.
What does the video say about sculptra (poly-l-lactic acid) stimulates collagen production over 6-12 months with?
Sculptra (poly-L-lactic acid) stimulates collagen production over 6-12 months with serial injections and has legitimate evidence for facial volume restoration, but no published trials support its use as a preventive treatment during ongoing GLP-1-induced weight loss.
What does the video say about the term 'ozempic face'?
The term 'Ozempic face' is a media label, not a clinical diagnosis. The skin changes it describes are cosmetic consequences of fat loss, not side effects of semaglutide or tirzepatide.
What does the video say about rate of weight loss appears to matter more than total?
Rate of weight loss appears to matter more than total weight lost for facial aging outcomes. Patients and clinicians should discuss loss rate when facial appearance is a concern.
What does the video say about photo-based surgical diagnosis of a celebrity without clinical examination?
Photo-based surgical diagnosis of a celebrity without clinical examination or patient consent is speculative, regardless of the physician's qualifications. Viewers should not treat it as confirmed medical history.
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Dr. Jennifer Armstrong, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.